Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. EVOK
EVOK logo

EVOK Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
4.31M
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
12.37M
EV/OCF(TTM)
--
P/S(TTM)
2.12
Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
Show More

Events Timeline

(ET)
2025-11-13
07:08:54
Evoke Pharma announces Q3 earnings per share of 45 cents, compared to a loss of 94 cents in the same period last year.
select
2025-11-04 (ET)
2025-11-04
07:02:37
QOL Medical to purchase Evoke Pharma for $11.00 per share in cash
select
2025-08-26 (ET)
2025-08-26
07:05:22
Evoke Pharma and EVERSANA Enhance GIMOTI Availability Through Partnership with Omnicell
select
2025-08-21 (ET)
2025-08-21
07:01:31
Evoke Pharma Reveals New GIMOTI Patent Listed in FDA Orange Book
select
2025-08-14 (ET)
2025-08-14
07:15:05
Evoke Pharma sees FY25 net product sales of approx $16M
select
2025-08-14
07:14:26
Evoke Pharma reports Q2 EPS (62c) vs (93c) last year
select
2025-08-06 (ET)
2025-08-06
07:29:26
Evoke Pharma announces issuance of new U.S. patent for GIMOTI
select
2025-07-09 (ET)
2025-07-09
08:31:28
Evoke Pharma receives notice of allowance for use of GIMOTI from USPTO
select

News

PRnewswire
8.5
2025-12-17PRnewswire
Evoke Pharma Acquired by QOL Medical for $11.00 Per Share
  • Successful Acquisition Offer: QOL Medical's wholly-owned subsidiary successfully acquired Evoke Pharma, offering $11.00 per share in cash, with approximately 1,164,862 shares validly tendered, representing 67.63% of the outstanding shares, indicating strong market support for the transaction.
  • Post-Merger Changes: Following the merger, Evoke became a wholly owned subsidiary of QOL Medical, with all untendered shares canceled and converted into cash rights, further streamlining the company's equity structure.
  • NASDAQ Delisting Plan: Evoke's common stock ceased trading on NASDAQ on December 17, 2025, with plans for prompt delisting and deregistration, marking a significant step in the company's strategic restructuring.
  • Focus on Rare Diseases: QOL Medical's commitment to improving the quality of life for patients with rare diseases will be strengthened by this acquisition, enhancing its competitive position in the market and driving the development and commercialization of new products.
Newsfilter
8.5
2025-12-17Newsfilter
Evoke Pharma Acquired by QOL Medical for $11.00 Per Share
  • Acquisition Completed: QOL Medical successfully acquired Evoke Pharma at $11.00 per share, obtaining approximately 67.63% of the outstanding shares, which marks Evoke as a wholly owned subsidiary and strengthens QOL's position in the rare disease market.
  • Transaction Timeline: The tender offer expired on December 15, 2025, without extension, demonstrating QOL Medical's commitment to the acquisition, which is expected to accelerate Evoke's product development and market introduction.
  • Market Reaction: Evoke's stock ceased trading on Nasdaq on December 17, 2025, with plans for delisting and deregistration, reflecting positive market expectations for the deal that may enhance QOL Medical's overall market value.
  • Strategic Integration: The acquisition incorporates Evoke's GIMOTI product into QOL Medical's portfolio, which is anticipated to enhance service capabilities for rare disease patients through resource and market channel integration, further expanding market share.
Globenewswire
7.0
2025-12-01Globenewswire
Halper Sadeh LLC Urges Shareholders of EVOK, FSFG, and BRY to Reach Out for Rights Consultation
  • Investigation of Companies: Halper Sadeh LLC is investigating Evoke Pharma, First Savings Financial Group, and Berry Corporation for potential violations of federal securities laws and breaches of fiduciary duties related to their recent sales.

  • Shareholder Rights: The firm encourages shareholders of the involved companies to learn about their rights and options, offering legal assistance on a contingent fee basis, meaning no upfront costs for legal fees.

  • Legal Support: Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, aiming to recover funds and implement corporate reforms.

  • Contact Information: Shareholders can reach out to attorneys Daniel Sadeh or Zachary Halper for free consultations regarding their legal rights and options.

Globenewswire
8.5
2025-12-01Globenewswire
Shareholder Notice: M&A Class Action Firm Ongoing Investigation into the Merger Involving TRUE, BRY, EVOK, and FSFG
  • Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.

  • TrueCar, Inc. Sale: TrueCar shareholders are set to receive $2.55 per share in cash following its sale to Fair Holdings, with a shareholder vote scheduled for December 22, 2025.

  • Berry Corporation Transaction: Berry Corporation shareholders will have their shares converted into 0.0718 shares of California Resources common stock, with a shareholder vote on December 15, 2025.

  • Evoke Pharma and First Savings Financial Group Sales: Evoke Pharma shareholders will receive $11.00 per share in cash from QOL Medical, while First Savings Financial Group shares will convert into 0.85 shares of First Merchants common stock, with respective deadlines for action on December 15 and December 19, 2025.

WSJ
7.0
2025-11-27WSJ
Gambling Firms Caution About Profit Decline Due to U.K. Tax Hikes
  • Impact of Tax Increases: Gambling companies like Flutter Entertainment and Entain anticipate reduced earnings due to the U.K. government's plans to increase taxes on online gambling operators.

  • Budget Measures: The U.K. budget includes higher levies for online gambling while offering some relief for betting shops, as part of efforts to improve public finances.

PRnewswire
7.0
2025-11-18PRnewswire
Halper Sadeh LLC Encourages AXTA, COMP, EVOK, JTAI Shareholders to Contact the Firm to Discuss Their Rights
  • Investigation of Companies: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales and mergers of several companies, including Axalta Coating Systems, Compass, Evoke Pharma, and Jet.AI.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options, as the firm may seek increased consideration or additional disclosures on their behalf.

Valuation Metrics

The current forward P/E ratio for Evoke Pharma Inc (EVOK.O) is -4.72, compared to its 5-year average forward P/E of 5.38. For a more detailed relative valuation and DCF analysis to assess Evoke Pharma Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
5.38
Current PE
-4.72
Overvalued PE
51.57
Undervalued PE
-40.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.02
Current EV/EBITDA
-0.01
Overvalued EV/EBITDA
0.14
Undervalued EV/EBITDA
-0.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.26
Current PS
0.50
Overvalued PS
9.15
Undervalued PS
-2.62

Financials

AI Analysis
Annual
Quarterly

Whales Holding EVOK

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Evoke Pharma Inc (EVOK) stock price today?

The current price of EVOK is 0 USD — it has increased 0

What is Evoke Pharma Inc (EVOK)'s business?

Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.

What is the price predicton of EVOK Stock?

Wall Street analysts forecast EVOK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVOK is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Evoke Pharma Inc (EVOK)'s revenue for the last quarter?

Evoke Pharma Inc revenue for the last quarter amounts to 4.28M USD, increased 61.40

What is Evoke Pharma Inc (EVOK)'s earnings per share (EPS) for the last quarter?

Evoke Pharma Inc. EPS for the last quarter amounts to -0.45 USD, decreased -52.13

How many employees does Evoke Pharma Inc (EVOK). have?

Evoke Pharma Inc (EVOK) has 3 emplpoyees as of March 12 2026.

What is Evoke Pharma Inc (EVOK) market cap?

Today EVOK has the market capitalization of 4.31M USD.